Date | Price Target | Rating | Analyst |
---|---|---|---|
10/4/2024 | $78.00 | Neutral | Goldman |
6/20/2024 | $115.00 | Peer Perform → Outperform | Wolfe Research |
12/11/2023 | $110.00 | Neutral → Buy | Citigroup |
7/19/2023 | $130.00 | Outperform | Robert W. Baird |
2/7/2023 | $150.00 | Overweight | Wells Fargo |
11/7/2022 | Underperform → Peer Perform | Wolfe Research | |
6/9/2022 | $180.00 → $155.00 | Buy → Neutral | Citigroup |
4/6/2022 | $105.00 | Underperform | Wolfe Research |
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
10-Q - iRhythm Technologies, Inc. (0001388658) (Filer)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
Zio ECG monitoring system is the only fourteen-day cardiac monitoring service in its category to receive Japanese regulatory approval as an improved device without a clinical trialZio ECG monitoring system previously received Japanese high medical needs designation, a unique distinction reflecting positive recommendation by the Japanese Heart Rhythm Society (JHRS)iRhythm will continue working towards reimbursement to enable market access in Japan, the world's second largest medical device marketJapan is the second largest ambulatory cardiac monitoring market in the world with an estimated 1.6 million tests prescribed annually – a number that is expected to continue to increase1-3 SAN FRAN
iRhythm's next-generation Zio® monitor demonstrated longer wear duration and analyzable time compared to the prior generation Zio® XT device.Longer wear duration and analyzable time may further improve diagnostic yield, building upon Zio XT service's superior yield among ambulatory cardiac monitoring services as demonstrated by the prior CAMELOT study findings.1The Zio monitor ECG device has been worn by over 1 million patients since launching in late 2023.2 SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced initial research findings on post-market, real-world performance of Zio® monitor, its next-generation Zio® long-term continuou
SAN FRANCISCO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has signed an exclusive license agreement with BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, to develop and commercialize certain patented technology assets within ambulatory cardiac monitoring (ACM). "As a natural complement to iRhythm's leading ambulatory cardiac monitoring platform, BioIntelliSense's multiparameter sensing technologies position us to significantly expand the capabilities of our product p
Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00
Wolfe Research upgraded iRhythm from Peer Perform to Outperform and set a new price target of $115.00
Citigroup upgraded iRhythm from Neutral to Buy and set a new price target of $110.00
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G - iRhythm Technologies, Inc. (0001388658) (Subject)
5 analysts have shared their evaluations of iRhythm Technologies (NASDAQ:IRTC) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $127.8, with a high estimate o
Truist Securities analyst David Rescott maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and lowers the price target from $145 to $134.
Morgan Stanley analyst Cecilia Furlong maintains iRhythm Technologies (NASDAQ:IRTC) with a Overweight and lowers the price target from $135 to $130.
SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $148.0 million, a 19.3% increase compared to second quarter 2023Gross margin of 69.9%, a 40-basis point increase compared to second quarter 2023Unrestricted cash, cash equivalents and marketable securities of $561.5 million as of June 30, 2024Increased fiscal year 2024 guidance for revenue, gross margin, and adjusted EBITDA Recent Operational Highlights R
SAN FRANCISCO, July 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2024 after the close of trading on Thursday, August 1, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leadi
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $131.9 million, a 18.4% increase compared to first quarter 2023Gross margin of 66.3%, a 160-basis point decline compared to first quarter 2023Unrestricted cash, cash equivalents and marketable securities of $569.1 million as of March 31, 2024Increased fiscal year 2024 revenue guidance to a range of $578 million to $588 million Recent Opera
iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved
A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer
SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)